Clinical case of a successful treatment of stage IV esophagal adenocarcinoma
https://doi.org/10.21294/1814-4861-2022-21-2-156-159
Abstract
Background. Esophageal adenocarcinoma is often diagnosed at an advanced stage. The overall five-year survival rate of metastatic esophageal adenocarcinoma is less than 15 %. The main treatment strategy is drug therapy. The search for new drugs is still ongoing. Therefore, the assessment of the effectiveness of currently existing options is of great significance.
Description of the clinical case. A 45-year-old patient with advanced esophageal cancer with omental, mediastinal and subclavian lymph node metastases received 4 cycles of CF chemotherapy and 3 cycles of DCF + trastuzumab chemotherapy. After 25 cycles of maintenance therapy with trastuzumab, stable disease was observed. There were no significant adverse events associated with the use of trastuzumab. Currently, the patient has no any symptoms of disease.
Conclusion. Trastuzumab for the treatment of HER2- overexpressing esophageal cancer was shown to be very effective. The presented clinical case demonstrates not only the feasibility of controlling metastatic disease using targeted therapy, but also maintaining a high level of quality of life.
About the Authors
A. V. Sergeeva
Republican Clinical Cancer Hospital named after S.G. Primushko
Russian Federation
Russian Federation
MD, Oncologist, Department of Anticancer Drug Therapy № 1
3, Truda St., 426009, Izhevsk, Russia
V. Yu. Vasiliev
Republican Clinical Cancer Hospital named after S.G. Primushko
Russian Federation
Russian Federation
MD, Oncologist, Department of Anticancer Drug Therapy № 1
3, Truda St., 426009, Izhevsk, Russia
S. V. Batov
Izhevsk State Medical Academy of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, PhD, Associate Professor of the Department of Oncology
281, Kommunarov St., 426034, Izhevsk, Russia
References
1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–49. doi: 10.3322/caac.21660.
2. Hur C., Miller M., Kong C.Y., Dowling E.C., Nattinger K.J., Dunn M., Feuer E.J. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013; 119(6): 1149–58. doi: 10.1002/cncr.27834.
3. Coleman H.G., Xie S.H., Lagergren J. The Epidemiology of Esophageal Adenocarcinoma. Gastroenterology. 2018; 154(2): 390–405. doi: 10.1053/j.gastro.2017.07.046.
4. Grady W.M., Yu M. Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus. Dig Dis Sci. 2018; 63(8): 2059–69. doi: 10.1007/s10620-018-5090-8.
5. di Pietro M., Canto M.I., Fitzgerald R.C. Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy. Gastroenterology. 2018; 154(2): 421–36. doi: 10.1053/j.gastro.2017.07.041.
6. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Esophageal and Esophagogastric Junction Cancers. 2021.
7. Ter Veer E., van den Ende T., Creemers A., de Waal L., van Oijen M.G.H., van Laarhoven H.W.M. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis. Acta Oncol. 2018; 57(12): 1599–1604. doi: 10.1080/0284186X.2018.1503421.
Review
For citations:
Sergeeva A.V., Vasiliev V.Yu., Batov S.V. Clinical case of a successful treatment of stage IV esophagal adenocarcinoma. Siberian journal of oncology. 2022;21(2):156-159. (In Russ.) https://doi.org/10.21294/1814-4861-2022-21-2-156-159
Views:
487
Email this article 
